Brief: Verve Therapeutics Receives U.S. FDA Fast Track Designation For Verve-102, An In Vivo Base Editing Medicine Targeting Pcsk9
11/04/2025 12:03
April 11 (Reuters) - Verve Therapeutics Inc VERV.O: VERVE THERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR VERVE-102, AN IN VIVO BASE EDITING MEDICINE TARGETING PCSK9 Source text: ID:nGNX3wj7H5 Further company coverage: VERV.O (((( Reuters.briefs@thomsonreuters.com ;));))